FAM89A Activators
FAM89A Activators are a class of compounds that enhance the functional activity of the FAM89A protein through various indirect biochemical and cellular pathways. For example, cyclin-dependent kinase inhibitors such as alsterpaullone can lead to the accumulation of proteins involved in the cell cycle, with which FAM89A may interact, thereby enhancing its activity. Phosphatase inhibitors like okadaic acid increase phosphorylation levels of proteins, which may include partners of FAM89A, thus indirectly promoting its activation. PKC inhibitors, including Bisindolylmaleimide I and Go 6983, can alter phosphorylation cascades that influence the functional state of FAM89A.
Further, the use of MEK inhibitors such as PD 98059 and U0126 can trigger compensatory responses within the cell that may result in the upregulation of signaling pathways involving FAM89A. PI3K inhibitorslike LY294002 and Wortmannin, by reducing PI3K/AKT signaling, can shift cellular equilibrium, leading to a homeostatic enhancement of FAM89A's activity. Rapamycin's inhibition of mTOR signaling can also stimulate a cellular adjustment, enhancing FAM89A function as part of a feedback mechanism. Inhibitors of MAPK pathways, such as SB203580 and SP600125, modulate stress and inflammatory signaling, which can indirectly lead to the activation of FAM89A by altering the cellular signaling landscape. Lastly, KN-93's inhibition of CaMKII can affect calcium signaling pathways, which could intersect with FAM89A's functional roles, suggesting that such an interaction can result in an enhancement of FAM89A activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor that leads to cell cycle arrest. By inhibiting CDKs, alsterpaullone can enhance the activity of FAM89A by causing the accumulation of cell cycle regulators that FAM89A may interact with or respond to, indirectly leading to its activation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A. Inhibition of these phosphatases can lead to increased phosphorylation levels of various proteins, which may include substrates or partners of FAM89A, thereby enhancing FAM89A activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). Inhibition of PKC can lead to alterations in phosphorylation patterns that might affect proteins interacting with or regulated by FAM89A, thereby indirectly enhancing its activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go 6983 is another PKC inhibitor with a slightly different specificity profile compared to Bisindolylmaleimide I. By modulating PKC activity, Go 6983 may influence signaling pathways that involve FAM89A, leading to its functional activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which is part of the MAPK/ERK pathway. Inhibition of MEK can lead to compensatory cellular responses that enhance the activity of FAM89A as the cell attempts to normalize signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that by reducing PI3K/AKT signaling can lead to alterations in downstream signaling pathways. These changes can enhance the activity of FAM89A by shifting cellular homeostasis and activating compensatory mechanisms that involve FAM89A. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor with a different binding profile from LY294002. By altering PI3K/Akt signaling, wortmannin can indirectly enhance the activity of FAM89A through compensatory cellular responses in signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, leading to downregulation of the mTORC1 pathway. This inhibition can enhance FAM89A activity by causing a cellular response that compensates for reduced protein synthesis and cell growth signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, affecting inflammatory and stress response pathways. Inhibition of p38 MAPK can enhance the activity of FAM89A as the cell adjusts to maintain signaling homeostasis. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, altering the JNK signaling pathway. This can enhance the activity of FAM89A by modulating stress response and apoptosis signaling pathways, where FAM89A may play a role. | ||||||